30% discount off Royal Society Notes and Records

BSHS members get an exclusive 30% off a personal subscription to Notes and Records.
Subscribe

20% discount off Ashgate publications

BSHS members get an exclusive 20% off all Ashgate publications.

Visit Ashgate

UNBRANDING MEDICINES: THE POLITICS, PROMISE, AND CHALLENGE OF GENERIC DRUGS

///UNBRANDING MEDICINES: THE POLITICS, PROMISE, AND CHALLENGE OF GENERIC DRUGS

UNBRANDING MEDICINES: THE POLITICS, PROMISE, AND CHALLENGE OF GENERIC DRUGS

CONFERENCE:

UNBRANDING MEDICINES: THE POLITICS, PROMISE, AND CHALLENGE OF GENERIC DRUGS

Sponsored by the Harvard Interfaculty Initiative on Medications and Society

Thursday, December 11, 5:00 pm — 7:00 pm, Sever Hall 113, Harvard Yard

Friday, December 12, 8:30 am — 6:00 pm, Tsai Auditorium, CGIS South S-010, 1730 Cambridge Street

A cross-disciplinary conference that will address the clinical, regulatory, economic, political, and cultural aspects of the generic drugs movement, featuring Janet Woodcock, Director of the FDA Center for Drug Evaluation and Research, Richard Crout, former Chief of the FDA Bureau of Drugs, Joshua Boger, founder and CEO of Vertex Pharmaceuticals, patient activist Jamie Love, patent attorney and generic drugs expert Alfred Engelberg, and faculty from Harvard Medical School, Harvard Business School, and the Departments of History of Science and Government of the Faculty of Arts and Sciences, among others. Sponsored by the Harvard Interfaculty Initiative on Medications and Society.

To register for the conference or for more information please contact [email protected] or visit the conference website at:

www.medsoc.harvard.edu/generics

By | 2010-12-12T10:57:27+00:00 December 12th, 2010|Conferences, Symposia & Workshops|Comments Off on UNBRANDING MEDICINES: THE POLITICS, PROMISE, AND CHALLENGE OF GENERIC DRUGS

About the Author: